Back to Search Start Over

AN2 halves head count, stops phase 3 trial after data disappoint.

Authors :
Taylor, Nick Paul
Source :
FierceBiotech; 8/9/2024, pN.PAG-N.PAG, 1p
Publication Year :
2024

Abstract

AN2 Therapeutics is rethinking its business in response to lackluster midphase data that have prompted a pivot to early-stage projects. [ABSTRACT FROM AUTHOR]

Subjects

Subjects :
CLINICAL trials
LAYOFFS
ANTIBIOTICS

Details

Language :
English
Database :
Complementary Index
Journal :
FierceBiotech
Publication Type :
Periodical
Accession number :
178936106

Tools

Authors Abstract Subjects Details